| Liraglutide and cardiovascular outcomes in type 2 diabetes SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ... New England Journal of Medicine 375 (4), 311-322, 2016 | 6984 | 2016 |
| Dapagliflozin in patients with chronic kidney disease HJL Heerspink, BV Stefánsson, R Correa-Rotter, GM Chertow, T Greene, ... New England Journal of Medicine 383 (15), 1436-1446, 2020 | 3451 | 2020 |
| Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals HC Gerstein, JFE Mann, Q Yi, B Zinman, SF Dinneen, B Hoogwerf, ... Jama 286 (4), 421-426, 2001 | 3260 | 2001 |
| Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis C Wanner, V Krane, W März, M Olschewski, JFE Mann, G Ruf, E Ritz New England Journal of Medicine 353 (3), 238-248, 2005 | 3004 | 2005 |
| Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention RT Gansevoort, R Correa-Rotter, BR Hemmelgarn, TH Jafar, ... The Lancet 382 (9889), 339-352, 2013 | 2333 | 2013 |
| Effect of the angiotensin-converting–enzyme inhibitor benazepril on the progression of chronic renal insufficiency G Maschio, D Alberti, G Janin, F Locatelli, JFE Mann, M Motolese, ... New England Journal of Medicine 334 (15), 939-945, 1996 | 2144 | 1996 |
| Chronic kidney disease: effects on the cardiovascular system EL Schiffrin, ML Lipman, JFE Mann Circulation 116 (1), 85-97, 2007 | 2106 | 2007 |
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial JFE Mann, RE Schmieder, M McQueen, L Dyal, H Schumacher, J Pogue, ... The Lancet 372 (9638), 547-553, 2008 | 2074 | 2008 |
| Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial JFE Mann, HC Gerstein, J Pogue, J Bosch, S Yusuf, Hope Investigators Annals of internal medicine 134 (8), 629-636, 2001 | 1858 | 2001 |
| Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised … Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with ... The Lancet 372 (9644), 1174-1183, 2008 | 1220 | 2008 |
| Liraglutide and renal outcomes in type 2 diabetes JFE Mann, DD Ørsted, K Brown-Frandsen, SP Marso, NR Poulter, ... New England Journal of Medicine 377 (9), 839-848, 2017 | 1173 | 2017 |
| Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk … M Van Der Velde, K Matsushita, J Coresh, BC Astor, M Woodward, ... Kidney international 79 (12), 1341-1352, 2011 | 1081 | 2011 |
| Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes H Haller, S Ito, JL Izzo Jr, A Januszewicz, S Katayama, J Menne, ... New England Journal of Medicine 364 (10), 907-917, 2011 | 1076 | 2011 |
| Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease R Kunz, C Friedrich, M Wolbers, JFE Mann Annals of internal medicine 148 (1), 30-48, 2008 | 1022 | 2008 |
| Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts RT Gansevoort, K Matsushita, M Van Der Velde, BC Astor, M Woodward, ... Kidney international 80 (1), 93-104, 2011 | 832 | 2011 |
| Urinary sodium and potassium excretion and risk of cardiovascular events MJ O'Donnell, S Yusuf, A Mente, P Gao, JF Mann, K Teo, M McQueen, ... Jama 306 (20), 2229-2238, 2011 | 702 | 2011 |
| Intensive supportive care plus immunosuppression in IgA nephropathy T Rauen, F Eitner, C Fitzner, C Sommerer, M Zeier, B Otte, U Panzer, ... New England Journal of Medicine 373 (23), 2225-2236, 2015 | 660 | 2015 |
| Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease GR Dagenais, Q Yi, JFE Mann, J Bosch, J Pogue, S Yusuf, ... American heart journal 149 (1), 54-60, 2005 | 569 | 2005 |
| Avosentan for overt diabetic nephropathy JFE Mann, D Green, K Jamerson, LM Ruilope, SJ Kuranoff, T Littke, ... Journal of the American Society of Nephrology 21 (3), 527-535, 2010 | 532 | 2010 |
| Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies A Mente, M O'Donnell, S Rangarajan, G Dagenais, S Lear, M McQueen, ... The Lancet 388 (10043), 465-475, 2016 | 524 | 2016 |
Salim YusufPopulation Health Research Institute, McMaster University and Hamilton Health SciencesVerified email at mcmaster.ca
